Company intelligence / Profile preview
Tcelltech GmbH
Mannheim, Baden-Württemberg, Germanytcelltech.eu ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Preclinical
01
Overview
Tcelltech GmbH is developing UNIPACT, a universal personalized adoptive cell therapy platform that rapidly identifies and engineers patient-specific tumor-reactive T cells using proprietary AI-driven discovery and non-integrating gene delivery technology. The approach aims to overcome current immunotherapy limitations by enabling fast production timelines suitable even for aggressive tumors and improving safety/efficacy over existing therapies. No published clinical data yet.
- Therapeutic areas
- Oncology
- Modalities
- Adoptive cell therapyGenetically engineered T cells (TCR-T)Non-viral gene delivery vectors
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Tcelltech GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tcelltech GmbH.